# The Feasibility of Florbetapir Quantitation

> **NCT01946243** · PHASE4 · COMPLETED · sponsor: **Avid Radiopharmaceuticals** · enrollment: 96 (actual)

## Conditions studied

- Alzheimers Disease

## Interventions

- **DRUG:** Florbetapir F18

## Key facts

- **NCT ID:** NCT01946243
- **Lead sponsor:** Avid Radiopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2015-06-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01946243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01946243, "The Feasibility of Florbetapir Quantitation". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01946243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*